Docetaxel is already a cornerstone in the treatment of metastatic BC [58], and targeting XRCC4 could further refine therapeutic efficacy by addressing DNA damage repair pathways, which are critical in TNBC [59]. The gene discussed is XRCC4; the disease is breast cancer.